The Stagnation of Vascular Device Technology

Palmaz JC. Bring that pioneering spirit back! A 25-year perspective on the vascular stent. Cardiovasc Intervent Radiol. 2007;30:1095–1098.

Palmaz JC. Intravascular stents in the last and the next 10 years. J Endovasc Ther. 2004;11(suppl II):II-200–II-206.

Sprague EA Palmaz JC. A model system to assess key vascular responses to biomaterials. J Endovasc Ther. 2005;12:594–604.

Palmaz JC Benson A Sprague EA. Influence of surface topography on endothelialization of intravascular metallic material. J Vasc Interv Radiol. 1999;10:439–444.

Sprague EA Tio F Ahmed SH et al Impact of parallel micro-engineered stent grooves on endothelial cell migration, proliferation, and function: an in vivo correlation study of the healing response in the coronary swine model. Circ Cardiovasc Interv 2012;5:499–507.

Vesga B Hernandez H Huiguera S et al Biological effect of microengineered grooved stents on strut healing: a randomized OCT-based comparative study in humans. Open Heart. 2017;4:e000521.

Moses JW Leon MB Popma JJ et al ; SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315–1323.

Bønaa KH Mannsverk J Wiseth R et al ; NORSTENT Investigators. Drug-eluting or bare-metal stents for coronary artery disease. N Engl J Med. 2016;375:1242–1252.

Heublein B Rohde R Koese V et al Biocorrosion of magnesium alloys: a new principle in cardiovascular technology? Heart. 2003;89:651–656.

Tamai H Igaki K Tsuji T et al A biodegradable poly-l-lactic acid coronary stent in the porcine coronary artery. J Interv Cardiol. 1999;12:443–449.

Tamai H Igaki K Kosuga K et al Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation. 2000;102:399–404.

Serruys PW Chevalier B Dudek D et al A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43–54.

Serruys PW Chevalier B Sotomi Y et al Comparison of an everolimus-eluting bioresorbable scaffold with an everolimus-eluting metallic stent for the treatment of coronary artery stenosis (ABSORB II): a 3 year, randomised, controlled, single-blind, multicentre clinical trial. Lancet. 2016;388:2479–2491.

Sorrentino S Giustino G Mehran R et al Everolimus-eluting bioresorbable scaffolds versus everolimus-eluting metallic stents. J Am Coll Cardiol. 2017;69:3055–3066.

Ippoliti E , ed. Heuristic Reasoning: Studies in Applied Philosophy, Epistemology and Rational Ethics. Switzerland: Springer International; 2015.

Makkar RR Fontana G Søndergaard L. Possible subclinical leaflet thrombosis in bioprosthetic aortic valves. N Engl J Med. 2016;374:1591–1592.

Major A Guidoin R Soulez G et al Implant degradation and poor healing after endovascular repair of abdominal aortic aneurysms: an analysis of explanted stent-grafts. J Endovasc Ther. 2006;13:457–467.

Ishihara T Iida O Inoue K et al Histological evaluation of a self-expanding stent-graft 23 months after implantation in the superficial femoral artery. J Endovasc Ther. 2017;24:746–750.

Guidoin R Marois Y Douville Y et al First-generation aortic endografts: analysis of explanted Stentor devices from the EUROSTAR registry. J Endovasc Ther. 2000;7:105–122.

Cao P De Rango P Verzini F et al Endoleak after endovascular aortic repair: classification, diagnosis and management following endovascular thoracic and abdominal aortic repair. J Cardiovasc Surg (Torino). 2010;51:53–69.

Palmaz JC Bailey S Marton D et al Influence of stent design and material composition on procedure outcome. J Vasc Surg. 2002;36:1031–1039.

Kasemo B Lausmaa J. Biomaterial and implant surfaces: On the role of cleanliness, contamination and preparation procedures. J Biomed Mater Res. 1988;22(A2 suppl):145–158.

Palmaz JC. Tissue-stent interactions and design considerations. AJR Am J Roentgenol. 1993;160:613–618.

Guidoin R Zhang Z Douville Y et al Commentary: Nitinol stent designs need to adhere to the 3Bs: biofunctionality, biodurability, and biocompatibility. J Endovasc Ther. 2014;21:240–242.